Can we use biomarkers and functional assays to implement personalized therapies in transplantation?

Transplantation

Volumn 87, Issue 11, 2009, Pages 1295-1601

  Sawitzki, Birgit ^a   Pascher, Andreas ^a   Babel, Nina ^a   Reinke, Petra ^a   Volk, Hans Dieter ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Assay; Biomarker; Tolerance

Indexed keywords

BIOLOGICAL MARKER; AUTOANTIBODY; HLA ANTIGEN; IMMUNOSUPPRESSIVE AGENT;

ASSAY; GRAFT REJECTION; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; PRIORITY JOURNAL; REVIEW; TRANSPLANTATION; ARTICLE; GENE EXPRESSION; GENE EXPRESSION REGULATION; HISTOCOMPATIBILITY; HUMAN; IMMUNOLOGICAL MONITORING; IMMUNOLOGY; INDIVIDUALITY; KIDNEY TRANSPLANTATION; METHODOLOGY; TRANSPLANTATION TOLERANCE;

AUTOANTIBODIES; BIOLOGICAL MARKERS; GENE EXPRESSION; GENE EXPRESSION REGULATION; GRAFT REJECTION; HLA ANTIGENS; HUMANS; IMMUNE TOLERANCE; IMMUNOSUPPRESSIVE AGENTS; INDIVIDUALITY; KIDNEY TRANSPLANTATION; MONITORING, IMMUNOLOGIC; TRANSPLANTATION IMMUNOLOGY; TRANSPLANTATION TOLERANCE;

EID: 67649574144     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181a6b2cf     Document Type: Review

References (66)

1. Kawai T, Cosimi AB, Spitzer TR, et al. HLA-mismatched renal transplantation without maintenance immunosuppression. N Engl J Med2008; 358: 353.
2. Keymeulen B, Vandemeulebroucke E, Ziegler AG, et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med2005; 352: 2598.
3. Hutchinson JA, Brem-Exner BG, Riquelme P, et al. A cell-based approach to the minimization of immunosuppression in renal transplantation. Transpl Int 2008; 21: 742.
4. Pascual J, Bloom D, Torrealba J, et al. Calcineurin inhibitor withdrawal after renal transplantation with alemtuzumab: Clinical outcomes and effect on T-regulatory cells. Am J Transplant 2008; 8: 1529.
5. Pirenne J, Kawai M. Tolerogenic protocol for intestinal transplantation. Transplant Proc 2006; 38: 1664.
6. Scandling JD, Busque S, Dejbakhsh-Jones S, et al. Tolerance and chimerism after renal and hematopoietic-cell transplantation. N Engl J Med 2008; 358: 362.
7. Donckier V, Troisi R, Le Moine A, et al. Early immunosuppression withdrawal after living donor liver transplantation and donor stem cell infusion. Liver Transpl 2006; 12: 1523.
8. Haller M, Oberbauer R. Calcineurin inhibitor minimization, withdrawal and avoidance protocols after kidney transplantation. Transpl Int 2009; 22: 69.
9. Pretagostini R, Cinti P, Lai Q, et al. Minimization of immunosuppressive therapy after long-term survival and immunological monitoring of recipients after kidney transplantation. Transpl Immunol 2008; 20: 3.
10. Nickel P, Presber F, Bold G, et al. Enzyme-linked immunosorbent spot assay for donor-reactive interferon-gamma-producing cells identifies T-cell presensitization and correlates with graft function at 6 and 12 months in renal-transplant recipients. Transplantation 2004; 78: 1640.
11. Pascher A, Proesch S, Pratschke J, et al. Rat cytomegalovirus infection interferes with anti-CD4 mAb-(RIB 5/2) mediated tolerance and induces chronic allograft damage. Am J Transplant 2006; 6: 2035.
12. Wu Z, Bensinger SJ, Zhang J, et al. Homeostatic proliferation is a barrier to transplantation tolerance. Nat Med 2004; 10: 87.
13. Wang T, Chen L, Ahmed E, et al. Prevention of allograft tolerance by bacterial infection with Listeria monocytogenes. J Immunol 2008; 180: 5991.
14. Pratschke J, Weiss S, Neuhaus P, et al. Review of nonimmunological causes for deteriorated graft function and graft loss after transplantation. Transpl Int 2008; 21: 512.
15. Reutzel-Selke A, Jurisch A, Denecke C, et al. Donor age intensifies the early immune response after transplantation. Kidney Int 2007; 71: 629.
16. Weiss S, Kotsch K, Francuski M, et al. Brain death activates donor organs and is associated with a worse I/R injury after liver transplantation. Am J Transplant 2007; 7: 1584.
17. Augustine JJ, Poggio ED, Heeger PS, et al. Preferential benefit of antibody induction therapy in kidney recipients with high pretransplant frequencies of donor-reactive interferon-gamma enzyme-linked immunosorbent spots. Transplantation 2008; 86: 529.
18. Pearl JP, Parris J, Hale DA, et al. Immunocompetent T-cells with a memory-like phenotype are the dominant cell type following antibodymediated T-cell depletion. Am J Transplant 2005; 5: 465.
19. Kreijveld E, Koenen HJ, van Cranenbroek B, et al. Immunological monitoring of renal transplant recipients to predict acute allograft rejection following the discontinuation of tacrolimus. PLoS ONE 2008; 3: e2711.
20. Roussey-Kesler G, Giral M, Moreau A, et al. Clinical operational tolerance after kidney transplantation. Am J Transplant 2006; 6: 736.
21. Seyfert-Margolis V, Turka LA. Marking a path to transplant tolerance. J Clin Invest 2008; 118: 2684.
22. Martinez-Llordella M, Puig-Pey I, Orlando G, et al. Multiparameter immune profiling of operational tolerance in liver transplantation. Am J Transplant 2007; 7: 309.
23. Martinez-Llordella M, Lozano JJ, Puig-Pey I, et al. Using transcriptional profiling to develop a diagnostic test of operational tolerance in liver transplant recipients. J Clin Invest 2008; 118: 2845.
24. Terasaki PI, Kreisler M, Mickey RM. Presensitization and kidney transplant failures. Postgrad Med J 1971; 47: 89.
25. Lachmann N, Terasaki PI, Schonemann C. Donor-specific HLA antibodies in chronic renal allograft rejection: A prospective trial with a four-year follow-up. Clin Transpl 2006: 171.
26. Volk HD, Kern F. Insights into the specificity and function of (allo)antigen- reactive T cells. Am J Transplant 2001; 1: 109.
27. Heeger PS, Greenspan NS, Kuhlenschmidt S, et al. Pretransplant frequency of donor-specific, IFN-gamma-producing lymphocytes is a manifestation of immunologic memory and correlates with the risk of posttransplant rejection episodes. J Immunol 1999; 163: 2267.
28. Bellisola G, Tridente G, Nacchia F, et al. Monitoring of cellular immunity by interferon-gamma enzyme-linked immunosorbent spot assay in kidney allograft recipients: Preliminary results of a longitudinal study. Transplant Proc 2006; 38: 1014.
29. Kim SH, Oh EJ, Kim MJ, et al. Pretransplant donor-specific interferongamma ELISPOT assay predicts acute rejection episodes in renal transplant recipients. Transplant Proc 2007; 39: 3057.
30. Andree H, Nickel P, Nasiadko C, et al. Identification of dialysis patients with panel-reactive memory T cells before kidney transplantation using an allogeneic cell bank. J Am Soc Nephrol 2006; 17: 573.
31. Augustine JJ, Poggio ED, Clemente M, et al. Hemodialysis vintage, black ethnicity, and pretransplantation antidonor cellular immunity in kidney transplant recipients. J Am Soc Nephrol 2007; 18: 1602.
32. Bestard O, Nickel P, Cruzado JM, et al. Circulating alloreactive T cells correlate with graft function in longstanding renal transplant recipients. J Am Soc Nephrol 2008; 19: 1419.
33. VanBuskirk AM, Burlingham WJ, Jankowska-Gan E, et al. Human allograft acceptance is associated with immune regulation. J Clin Invest2000; 106: 145.
34. Pelletier RP, Bickerstaff AA, Adams PW, et al. Evaluation of immune regulation in transplant patients using the trans vivo delayed type hypersensitivity assay. Hum Immunol 2007; 68: 514.
35. Louis S, Braudeau C, Giral M, et al. Contrasting CD25hiCD4-T cells/ FOXP3 patterns in chronic rejection and operational drug-free tolerance. Transplantation 2006; 81: 398.
36. Braudeau C, Racape M, Giral M, et al. Variation in numbers of CD4-CD25highFOXP3-T cells with normal immuno-regulatory properties in long-term graft outcome. Transpl Int 2007; 20: 845.
37. Brouard S, Dupont A, Giral M, et al. Operationally tolerant and minimally immunosuppressed kidney recipients display strongly altered blood T-cell clonal regulation. Am J Transplant 2005; 5: 330.
38. Codarri L, Vallotton L, Ciuffreda D, et al. Expansion and tissue infiltration of an allospecific CD4-CD25-CD45RO-IL-7Ralphahigh cell population in solid organ transplant recipients. J Exp Med 2007; 204: 1533.
39. Sawitzki B, Reinke P, Volk HD, et al. Autoimmunity and transplantation: A meeting at the crossroads in Berlin. Nat Immunol 2008; 9: 447.
40. Li Y, Koshiba T, Yoshizawa A, et al. Analyses of peripheral blood mononuclear cells in operational tolerance after pediatric living donor liver transplantation. Am J Transplant 2004; 4: 2118.
41. Schlaf G, Altermann WW, Rothhoff A. Soluble CD30 serum level-An adequate marker for allograft rejection of solid organs? Histol Histopathol 2007; 22: 1269.
42. Heinemann FM, Rebmann V, Witzke O, et al. Association of elevated pretransplant sCD30 levels with graft loss in 206 patients treated with modern immunosuppressive therapies after renal transplantation. Transplantation 2007; 83: 706.
43. Pelzl S, Opelz G, Wiesel M, et al. Soluble CD30 as a predictor of kidney graft outcome. Transplantation 2002; 73: 3.
44. Susal C, Pelzl S, Dohler B, et al. Identification of highly responsive kidney transplant recipients using pretransplant soluble CD30. J Am Soc Nephrol 2002; 13: 1650.
45. Susal C, Pelzl S, Opelz G. Strong human leukocyte antigen matching effect in nonsensitized kidney recipients with high pretransplant soluble CD30. Transplantation 2003; 76: 1231.
46. Altermann W, Schlaf G, Rothhoff A, et al. High variation of individual soluble serum CD30 levels of pre-transplantation patients: sCD30 a feasible marker for prediction of kidney allograft rejection? Nephrol Dial Transplant 2007; 22: 2795.
47. Avihingsanon Y, Ma N, Pavlakis M, et al. On the intraoperative molecular status of renal allografts after vascular reperfusion and clinical outcomes. J Am Soc Nephrol 2005; 16: 1542.
48. Sawitzki B, Bushell A, Steger U, et al. Identification of gene markers for the prediction of allograft rejection or permanent acceptance. Am J Transplant 2007; 7: 1091.
49. Lipman ML, Stevens AC, Bleackley RC, et al. The strong correlation of cytotoxic T lymphocyte-specific serine protease gene transcripts with renal allograft rejection. Transplantation 1992; 53: 73.
50. Lipman ML, Stevens AC, Strom TB. Heightened intragraft CTL gene expression in acutely rejecting renal allografts. J Immunol 1994; 152: 5120.
51. Nickel P, Lacha J, Ode-Hakim S, et al. Cytotoxic effector molecule gene expression in acute renal allograft rejection: Correlation with clinical outcome; histopathology and function of the allograft. Transplantation2001; 72: 1158.
52. Hoffmann SC, Hale DA, Kleiner DE, et al. Functionally significant renal allograft rejection is defined by transcriptional criteria. Am J Transplant 2005; 5: 573.
53. Sarwal M, Chua MS, Kambham N, et al. Molecular heterogeneity in acute renal allograft rejection identified by DNA microarray profiling. N Engl J Med 2003; 349: 125.
54. Sabek O, Dorak MT, Kotb M, et al. Quantitative detection of T-cell activation markers by real-time PCR in renal transplant rejection and correlation with histopathologic evaluation. Transplantation 2002; 74: 701.
55. Simon T, Opelz G, Wiesel M, et al. Serial peripheral blood perforin and granzyme B gene expression measurements for prediction of acute rejection in kidney graft recipients. Am J Transplant 2003; 3: 1121
56. Vasconcellos LM, Schachter AD, Zheng XX, et al. Cytotoxic lymphocyte gene expression in peripheral blood leukocytes correlates with rejecting renal allografts. Transplantation 1998; 66: 562.
57. Alakulppi NS, Kyllonen LE, Partanen J, et al. Diagnosis of acute renal allograft rejection by analyzing whole blood mRNA expression of lymphocyte marker molecules. Transplantation 2007; 83: 791.
58. Tatapudi RR, Muthukumar T, Dadhania D, et al. Noninvasive detection of renal allograft inflammation by measurements of mRNA for IP-10 and CXCR3 in urine. Kidney Int 2004; 65: 2390.
59. Matz M, Beyer J, Wunsch D, et al. Early post-transplant urinary IP-10 expression after kidney transplantation is predictive of short- and longterm graft function. Kidney Int 2006; 69: 1683.
60. Brouard S, Mansfield E, Braud C, et al. Identification of a peripheral blood transcriptional biomarker panel associated with operational renal allograft tolerance. Proc Natl Acad Sci USA 2007; 104: 15448.
61. Hricik DE, Rodriguez V, Riley J, et al. Enzyme linked immunosorbent spot (ELISPOT) assay for interferon-gamma independently predicts renal function in kidney transplant recipients.AmJ Transplant 2003; 3: 878.
62. Nather BJ, Nickel P, Bold G, et al. Modified ELISPOT technique-Highly significant inverse correlation of post-Tx donor-reactive IFNgammaproducing cell frequencies with 6 and 12 months graft function in kidney transplant recipients. Transpl Immunol 2006; 16: 232.
63. Boskovic S, Kawai T, Smith RN, et al. Monitoring antidonor alloantibodies as a predictive assay for renal allograft tolerance/long-term observations in nonhuman primates. Transplantation 2006; 82: 819.
64. Terasaki PI, Cai J. Human leukocyte antigen antibodies and chronic rejection: From association to causation. Transplantation 2008; 86: 377.
65. van Besouw NM, van der Mast BJ, de Kuiper P, et al. Donor-specific T-cell reactivity identifies kidney transplant patients in whom immunosuppressive therapy can be safely reduced. Transplantation2000; 70: 136.
66. Braudeau C, Ashton-Chess J, Giral M, et al. Contrasted blood and intragraft toll-like receptor 4 mRNA profiles in operational tolerance versus chronic rejection in kidney transplant recipients. Transplantation2008; 86: 130.